We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Apellis Pharmaceuticals Inc
5 own
11 watching
Current Price
$0
$2.29
(4.54%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
5,577.93M
52-Week High
70
52-Week Low
33.32
Average Volume
1.16M
Dividend Yield
--
P/E Ratio
--
Market Capitalization5,577.93M52-Week High7052-Week Low33.32Average Volume1.16MDividend Yield--P/E Ratio--What does the Apellis Pharmaceuticals Inc do?
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company s lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
Read More
How much money does Apellis Pharmaceuticals Inc make?
News & Events about Apellis Pharmaceuticals Inc.
Ticker Report
14days ago
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS Get Rating) insider Pascal Deschatelets sold 12,000 shares of the businesss stock in a transaction dated Monday, January 9th. The stock was sold at an average price of $46.08, for a total transaction of $552,960.00. Following the sale, the ...
Zolmax
14days ago
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS Get Rating) insider Pascal Deschatelets sold 12,000 shares of the firms stock in a transaction that occurred on Monday, January 9th. The stock was sold at an average price of $46.08, for a total transaction of $552,960.00. Following the completion of the ...
Zolmax
15days ago
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS Get Rating) insider Federico Grossi sold 2,500 shares of the companys stock in a transaction on Thursday, January 5th. The stock was sold at an average price of $48.79, for a total value of $121,975.00. Following the sale, the insider now ...
Globe Newswire
21days ago
WALTHAM, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that leading retina specialist Caroline Baumal, M.D., has joined Apellis as chief medical officer. Dr. Baumal replaces Federico...
Benzinga
23days ago
Latest Ratings for APLS
DateFirmActionFromTo Mar 2022Goldman SachsMaintainsBuy Mar 2022Raymond JamesMaintainsStrong Buy Jan 2022Raymond JamesMaintainsStrong Buy
View More Analyst Ratings for APLS
View the Latest Analyst Ratings
read more...
Frequently Asked Questions
Frequently Asked Questions
What is Apellis Pharmaceuticals Inc share price today?
Can Indians buy Apellis Pharmaceuticals Inc shares?
How can I buy Apellis Pharmaceuticals Inc shares from India?
Can Fractional shares of Apellis Pharmaceuticals Inc be purchased?
What are the documents required to start investing in Apellis Pharmaceuticals Inc stocks?
What is today’s traded volume of Apellis Pharmaceuticals Inc?
What is today’s market capitalisation of Apellis Pharmaceuticals Inc?
What is the 52-Week High and Low Range of Apellis Pharmaceuticals Inc?
What percentage is Apellis Pharmaceuticals Inc down from its 52-Week High?
What percentage is Apellis Pharmaceuticals Inc up from its 52-Week Low?
Current Price
$0
$2.29
(4.54%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.